Clearmind Medicine wins Yale IRB clearance to recruit patients for CMND-100 trial parts B and C
CMND•Yale IRB clears recruitment for later CMND-100 trial parts
Clearmind Medicine won Yale University IRB clearance to start recruiting patients for Parts B and C of its CMND-100 Phase I/II trial.
The green light expands enrollment at Yale alongside existing recruiting sites, supporting development of the non-hallucinogenic AUD candidate.
Part A safety readout met the primary endpoint in 24 participants, with no serious adverse events reported.
